Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-011636
Filing Date
2024-08-08
Accepted
2024-08-08 16:57:24
Documents
57
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20240630x10q.htm   iXBRL 10-Q 1962743
2 EX-31.1 tbph-20240630xex31d1.htm EX-31.1 13465
3 EX-31.2 tbph-20240630xex31d2.htm EX-31.2 14242
4 EX-32 tbph-20240630xex32.htm EX-32 16251
  Complete submission text file 0001558370-24-011636.txt   6321129

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20240630.xsd EX-101.SCH 41733
6 EX-101.CAL tbph-20240630_cal.xml EX-101.CAL 45923
7 EX-101.DEF tbph-20240630_def.xml EX-101.DEF 140966
8 EX-101.LAB tbph-20240630_lab.xml EX-101.LAB 343208
9 EX-101.PRE tbph-20240630_pre.xml EX-101.PRE 230152
60 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20240630x10q_htm.xml XML 962065
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 241189373
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)